Market Overview

Renal Anemia| A Drug Pipeline Analysis Report 2018| Technavio

Share:

Technavio has announced their latest pipeline analysis report on the
drug pipeline for renal
anemia
. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat renal anemia.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180813005325/en/

Technavio has published a new report on the drug development pipeline for renal anemia, including a  ...

Technavio has published a new report on the drug development pipeline for renal anemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Renal anemia: Market overview

The significant reduction in the circulation of red blood cells in the
body causes anemia. It is one of the most common symptoms of chronic
kidney disease. During this condition, kidneys cannot produce
erythropoietin, a hormone that prompts bone marrow to produce red blood
cells. Red blood cells contain hemoglobin, which carries oxygen to the
organs and tissues of the body. The red blood cells in the people with
anemia carry less oxygen, thereby affecting the tissues and organs
associated mainly with the heart and brain. Renal anemia, also known as
anemia owing to chronic kidney disease, is the loss of kidney functions.
It is often associated with conditions such as fatigue, weakness, and
headache, affecting the heart and brain adversely.

According to a senior market research analyst at Technavio, "As per
the National Institutes of Health, anemia is likely to develop in the
early stages of chronic kidney disease, when someone has 20% to 50% of
normal kidney function. It is recommended that erythropoietin is the
best treatment for the patients with anemia, as it will reduce the need
for red blood cell transfusions."

Renal anemia: Segmentation analysis

This pipeline analysis report segments the renal anemia market based on
therapies employed (monotherapy), RoA (oral, IV, subcutaneous,
IV+subcutaneous, and parenteral), therapeutic modality (recombinant
erythropoietin, small molecule, and anticalin protein), targets
(erythropoietin, HIF-PHI, and hepcidin), MoA (erythropoietin stimulator,
HIF-PHI inhibitor, and hepcidin antagonist), geographical segmentation
(Japan, Russia, Australia, and Germany) and recruitment status (active,
not recruiting, and recruiting). It provides an in-depth analysis of the
prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

Based on the route of administration, around 32% of the molecules that
are being investigated for the treatment of renal anemia are
administered through oral medications.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!